^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

452P - Predicting response to bevacizumab in colorectal cancer by integrating radiomics to clinical and genomic features

Published date:
09/13/2021
Excerpt:
In our retrospective analysis, Notch signalling pathway was associated with resistance to anti-vascular endothelial growth factor (VEGF) therapy in patients with metastatic colorectal cancer (mCRC)....NICD and JAG1 expression was associated with response to bevacizumab (p<0.05).